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Abstract: Atrial fibrillation is the most common of the serious cardiac rhythm disturbances and 
is responsible for substantial morbidity and mortality. Amiodarone is currently one of the most 
widely used and most effective antiarrhythmic agents for atrial fibrillation. But during chronic 
usage amiodarone can cause some serious extra cardiac adverse effects, including effects on the 
thyroid. Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, 
with two molecular changes, and with a better side effect profile. Dronedarone is a multichan-
nel blocker and, like amiodarone, possesses both a rhythm and a rate control property in atrial 
fibrillation. The US Food and Drug Administration approved dronedarone for atrial fibrillation 
on July 2, 2009. In this review, we discuss the role of dronedarone in atrial fibrillation.
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Introduction
Atrial fibrillation (AF) is the most common of the serious cardiac rhythm disturbances 
and is responsible for substantial morbidity and mortality. The prevalence of AF 
is almost 1% and it is estimated that by the year 2050, approximately 5 million subjects 
will have AF in the United States.1 Currently, there are two major treatment strategies 
for AF: rate control and rhythm control. Sustained sinus rhythm is associated with an 
improved quality of life and improved exercise performance.2
Rationale for dronedarone
Currently amiodarone is one of the most widely used and most effective antiarrhythmic 
agents2 with little proarrhythmic potential.3 But during chronic usage amiodarone 
and its active metabolite desethylamiodarone can cause some serious extra cardiac 
adverse effects, including effects on the thyroid.2 Therefore there is a need for the 
development of safer and effective antiarrythmics agents. Amiodarone is an iodinated 
benzofuran derivative and contains 37% of organic iodine by weight. Amiodarone 
itself and its high iodine content can cause subclinical to overt thyroid dysfunction, 
manifesting either amiodarone-induced hypothyroidism or amiodarone-induced 
thyrotoxicosis. About 15% to 28% of patients develop thyroid dysfunction after 
2 to 3 years of therapy, a risk that increases with higher doses. Moreover, amiodarone 
is lipophilic because of its iodine content, thus accumulates in adipose tissue and 
highly perfused organs like the liver, lung, cornea, and skin. In addition, because of 
its long half-life of up to 100 days, high iodine levels persist for 6 months after 
discontinuation of the drug.4Vascular Health and Risk Management 2009:5 636
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Dronedarone is a newer benzofuran derivative with a 
structural resemblance to amiodarone, with two molecular 
changes: it lacks the iodine moiety and it has a methane 
sulfonyl group that decreases lipophilicity, resulting in a 
shorter half-life and lower tissue accumulation. In vitro 
the amiodarone metabolite N-desethylamiodarone (DEA) 
strongly inhibited T3 binding to thyroid hormone receptor 
(TR), both TRα1 and TRb1, within the same order of 
magnitude, whereas the active metabolite of dronedarone 
N-debutlydronadarone (DBD) was shown to inhibit T3 bind-
ing to TRα1 but much less so to TRb1. This isoform selectivity 
may explain the effects of dronedarone on the heart (a mainly 
TRα1 organ) and the lack of effect on the liver (a mainly TRb1 
organ) with little effect on plasma thyroid hormone.5 The 
steady-state serum level of dronedarone is achieved in 5 to 
7 days. The elimination half-life of dronedarone is 24 hours. 
It is cleared by nonrenal mechanism. Like amiodarone, oral 
bioavailability is increased 2- to 3-fold when taken with 
food. It is well absorbed after oral administration (70% to 
100%). The bioavailability is relatively low (15%) because 
of extensive hepatic first-pass metabolism by cytochrome 
P450 (CYP) 3A4 and CYP2D6, thus requiring twice-daily 
dosing to achieve steady-state serum levels.4
Dronedarone has been shown to exhibit even less 
reverse use-dependency of repolarization than that found 
with amiodarone, which may provide better cardiac safety.6 
In patch-clamp experiments in canine ventricular myocytes, 
10 µM dronedarone markedly reduced the rapid component 
of the delayed rectifier potassium current (97%, P  0.05) 
and the L-type calcium current (76.5%, P  0.05). In the 
same experimental study on dog myocytes, acute superfusion 
of dronedarone shortened the APD in Purkinje fibres (at 1 Hz 
from 309.6 ± 11.8 to 287.1 ± 10.8 ms, P  0.05) and reduced 
the incidence of early and delayed after depolarizations 
induced by dofetilide and strophantidine in Purkinje fibers. 
Chronic treatment with dronedarone for 4 weeks, unlike 
chronic administration of amiodarone, did not lengthen sig-
nificantly the QTc interval of the electrocardiogram.7
In multicellular preparations of guinea pig ventricular 
cells, dronedarone (3, 10, and 30 µM) decreased maximum 
rate of rise of action potential (dV/dt max) with a 
concentration- and frequency-dependent relationship.8 
Similarly, under whole-cell patch clamp on human atrial 
myocytes, amiodarone inhibited I (Na) by only 41% at 3 µM 
while dronedarone inhibited I (Na) almost completely, by 
97% at 3 µM.9 Thus dronedarone inhibits I (Na) significantly 
in single human atrial cells and exhibits class I antiarrhythmic 
properties.
In patch-clamp technique guinea pig atrial cell, 
dronedarone inhibited the muscarinic acetylcholine receptor-
operated K+ current (IK(ACh)) either by depressing the func-
tion of KACh channel itself or associated with GTP-binding 
proteins. Compared with amiodarone, dronedarone is an 
approximately 100 times more potent inhibitor on IK(ACh). 
This property may be involved, at least in part, in the 
antiarrhythmic action of dronedarone against AF, as vagal 
activation plays a role in the pathophysiology of AF.10
Dronedarone is a multichannel blocker, as it decreases 
delayed-rectifier K+ current I (Kr), slowly activating 
delayed-rectifier K+ current I (Ks), and inward rectifier 
potassium current I (K1), L-type Ca2+ current I (Ca (L)) 
and maximum rate of rise of action potential (dV/dt max) 
with a concentration- and frequency-dependent relationship 
(I (Na)).7,8 Thus dronedarone, like amiodarone, possesses 
both rhythm and a rate-control properties as it has class I to 
IV antiarrhythmic activity.
Antiadrenergic property
In anesthetized, atropinized dogs, both amiodarone and 
dronedarone were shown to inhibit alpha-adrenoceptor 
(adrenaline)-induced increase in blood pressure to similar 
extents. In the same study, inhibition of beta 1-adrenoceptor 
(isoprenaline)-induced increase in heart rate was less marked 
in dronedarone than amiodarone, whereas dronedarone was 
more potent than amiodarone in inhibiting beta 2-adrenoceptor 
(isoprenaline)-induced increase in blood pressure. However, 
in conscious dogs, both dronedarone and amiodarone inhibited 
isoprenaline-induced increases in heart rate by approximately 
the same amount. Thus, like amiodarone, dronedarone can 
partially inhibit the effects of stimulation of the adrenoceptor 
system that may play a pivotal role in the onset of severe 
ventricular rhythm disturbances.11 In a study on conscious 
dogs with healed myocardial infarction, dronedarone displayed 
antiadrenergic actions comparable to those of amiodarone. 
Both dronedarone and amiodarone significantly reduced 
the exercise-induced tachycardia and, at the highest dose, 
decreased the isoproterenol-induced tachycardia and did not 
impair the resting left ventricular function.12
Preclinical studies suggest that dronedarone is more 
efficacious in reducing ventricular arrhythmias. In a rat 
model, during a 20-minute period of ischemia, dronedarone 
significantly reduced the incidence of ventricular fibrillation 
(VF) from 80% to 30% (P  0.05) at 3 mg/kg and eliminated 
VF and mortality at 10 mg/kg. In contrast, amiodarone 
at 10 mg/kg reduced significantly only the incidence of 
mortality during ischemia (from 60% to 0%, P  0.01), Vascular Health and Risk Management 2009:5 637
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while having no significant effect on 3 mg/kg. On reperfusion 
(after a 5-minute period of ischemia), dronedarone reduced 
significantly the incidence of mortality (from 90 to 20%, 
P  0.01) at 1 mg/kg and eliminated VF and mortality when 
administered at 3 and 10 mg/kg. Amiodarone (10 mg/kg iv) 
eliminated completely reperfusion-induced VF and mortality 
while having no significant effect at 1 and 3 mg/kg.13 Simi-
larly in anesthetized pigs, dronedarone was more potent 
than amiodarone in reducing ischemia-induced ventricular 
arrhythmias.14
Clinical studies (Table 1)
DAFNe trial
The Dronedarone Atrial FibrillatioN study after Electrical 
Cardioversion (DAFNE) was the first double-blind, randomized, 
placebo controlled trial designed to evaluate the efficacy and 
safety of dronedarone.15 270 patients with persistent AF were 
randomly allocated to 800, 1200, 1600 mg daily doses of drone-
darone or placebo in 50 centres and 11 countries. The main 
analysis was conducted on 199/270 patients, who entered the 
maintenance phase following pharmacological cardioversion 
or, if unsuccessful, DC cardioversion. The primary outcome 
was time to first documented AF recurrence. Secondary study 
endpoints were spontaneous conversion of AF following 
randomization, heart rate in case of AF recurrence and the 
incidence of side effects. 6-month follow-up showed that treat-
ment with dronedarone 800 mg significantly prolonged the time 
to AF recurrence with a median time to recurrence of 60 days 
vs 5.3 days in the placebo group (relative risk reduction 55% 
[95% CI, 28% to 72%] P = 0.001).
The incidence of spontaneous conversion to sinus rhythm 
was associated with a significant dose-effect relationship 
(P = 0.0261). Patients in the dronedarone 800, 1200, and 
1600 mg groups exhibited 5.8%, 8.2%, and 14.8% conversion 
rates respectively, vs 3.1% on placebo. At the time of first 
AF recurrence, dronedarone appeared to slow the ventricular 
response in a dose-dependent fashion. Patients receiving 
800, 1200, or 1600 mg dronedarone had their ventricular rate 
Table 1 Summary of clinical trials
Trial Subjects enrolled Follow-up period Main outcome Common side effects
DAFNe15 270 6 months First AF recurrence was 
5.8% with 800 mg, 8.2% with 
1200 mg and 14.8% with 
1600 mg dronedarone vs 
3.1% in placebo (P = 0.0261)
Gastrointestinal
eURiDiS 
and ADONiS16
612 in eURiDiS 
and 625 in ADONiS
12 months First recurrence of AF/AFL 
was 64.1% with dronedar-
one vs 75.2% with placebo 
(P  0.001)
Gastrointestinal (diarrhea)
eRATO17 174 6 months Reduction of 11.7 beats per 
minute in ventricular rate at 
day 14 (P  0.0001) – this 
effect was sustained for 
the duration of trial (–8.8 
beat/minute at 4 months) 
(P  0.001)
infections 
Mild increase in serum 
creatinine levels
ANDROMeDA18 627 13 months (including 
additional 6 months 
after premature 
discontinuation 
of study)
Premature termination of 
trial due to excess mortality 
related to the worsening of 
heart failure in dronedarone 
group (hazard ratio of 2.13; 
95% Ci 1.07 to 4.25; P = 0.03)
worsening heart failure 
increase in serum creatinine 
levels
ATHeNA21 4628 21 months First hospitalization due 
to cardiovascular events 
or death was 31.9% in 
dronedarone group vs 39.4% 
in placebo group (hazard 
ratio of 0.76; 95% Ci 0.69 to 
0.84; P  0.001)
Gastrointestinal (diarrhea, 
nausea) increase in serum 
creatinine levels 
Rash Bradycardia
Abbreviations: AF, atrial fibrillation; AFL, atrial flutter; CI, confidence interval.Vascular Health and Risk Management 2009:5 638
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reduced by 13.2, 19.2, and 17.8 bpm on average, respectively, 
compared to those on placebo (P = 0.0001). Twenty-two 
(10.8%) dronedarone patients discontinued treatment due 
to adverse events. In the 800 mg, 1200 mg and 1600 mg 
dronedarone groups, the discontinuation rates were 3.9%, 
7.6% and 22.6%, respectively. The most common cause 
of drug discontinuation was gastrointestinal side effects. 
Importantly no evidence of thyroid, ocular, or pulmonary 
toxicity was observed. There were no proarrhythmic 
reactions. Drug-induced QT prolongation was noticed only 
in the 1600 mg group and the effect of dronedarone on the 
QT interval remained modest. Dronedarone also proved to 
be hemodynamically well tolerated. Thus the DAFNE trial 
showed that dronedarone, at an 800 mg daily dose, appears 
to be effective and safe for the prevention of AF relapses 
after cardioversion at a 6-month follow-up.
eURiDiS and ADONiS trials
The results of DAFNE provided promising role of drone-
darone (400 mg bid) in prevention of AF recurrence and 
later it was evaluated by two similar double-blind, placebo-
controlled, multicenter, multinational, pivotal phase III 
studies with similar study protocols to determine the efficacy 
of dronedarone (400 mg bid) for the maintenance of normal 
sinus rhythm after electrical, pharmacological, or spontaneous 
conversion of AF or AFL (atrial flutter). The European Trial 
in Atrial Fibrillation or Flutter Patients Receiving Drone-
darone for the Maintenance of Sinus Rhythm (EURIDIS) 
was carried out at 65 centers in 12 European countries and 
the American-Australian-African Trial with Dronedarone 
in Atrial Fibrillation/Flutter Patients for the Maintenance of 
Sinus Rhythym (ADONIS) at 101 centers in USA, Canada, 
Australia, South Africa and Argentina.16
Male and female patients over 21 years of age were 
enrolled provided they had at least one episode of AF (as seen 
on electrocardiography) in the preceding 3 months, and were 
in sinus rhythm for at least 1 hour before randomization. 
Patients previously treated with amiodarone were permit-
ted, and were enrolled immediately after its discontinuation. 
Eligible patients (n = 612 in EURIDIS and n = 625 in 
ADONIS) were randomly assigned in a 2:1 ratio to receive 
either 400 mg of oral dronedarone twice daily or a match-
ing placebo for 1 year. Follow-up visits were scheduled for 
review of symptoms, assessment of vital signs, and perfor-
mance of electrocardiography on days 7, 14, and 21 and at 
2, 4, 6, 9, and 12 months. The primary endpoint was the time 
to the first documented recurrence of AF/AFL, defined as 
an episode lasting for at least 10 minutes and confirmed by 
two consecutive recordings on 12-lead electrocardiography 
or Tran telephonic monitoring. The secondary endpoints were 
severity of symptoms related to AF/AFL during recordings of 
12-lead electrocardiography or Tran telephonic monitoring 
and the mean ventricular rate during the first recurrence.
In EURIDIS, the median time to relapse was 96 days 
in the dronedarone group and 41 days in the placebo group 
and in ADONIS it was 158 days in the dronedarone group 
and 59 days in the placebo group. For the two trials com-
bined, the median times to recurrence were 116 days in 
the dronedarone group and 53 days in the placebo group. 
Combining data for the two trials, at 12 months, the rates of 
recurrence were 64.1% in the dronedarone group and 75.2% 
in the placebo group (hazard ratio, 0.75; 95% CI, 0.65 to 0.87; 
P  0.001). When the data for the two trials were analyzed 
separately, the results were similar with reductions in the risk 
of AF/AFL recurrence over 1 year by 29% (P = 0.0059) and 
26% (P = 0.0244) in EURIDIS and ADONIS, respectively. 
Mean ventricular rate during first AF/AFL recurrence was 
102 and 104 bpm in the dronedarone group of EURIDIS and 
ADONIS, respectively, whereas the the corresponding rates 
in the placebo groups were 117 and 116 bpm, respectively 
(P  0.001 and P  0.001, respectively). Combining the 
pooled data from trials, 37.7% of patients in the dronedar-
one group and 46.0% of patients in the placebo group had 
symptomatic recurrences (P  0.001 by the log-rank test). 
In both trials, dronedarone was superior to placebo in variety 
of patient subgroups including hypertension, structural heart 
disease, and previous amiodarone use.
There was no evidence of pulmonary or thyroid toxicity 
in dronedarone group. The incidence of hyperthyroidism in 
dronedarone group (8.4%) was significantly lower than in 
placebo group (14.1%) (P = 0.002), and the incidence of 
hypothyroidism (5.5%) in dronedarone group was slightly 
higher than in placebo group (3.5%) but not significantly 
(P = 0.15). The incidence of photosensitive rash and reac-
tion was not significant (0.7% in dronedarone group vs 
0.2% in placebo group [P = 0.44]). The main side effect of 
dronedarone group was diarrhea at high doses. In addition, 
there was a higher incidence of elevated serum creatinine 
levels in the dronedarone group than in the placebo group 
(2.4% vs 0.2%, P = 0.004). Serious side effects were rare 
and were reported with similar frequency in both groups 
(16.5% dronedarone vs 13.5% placebo). In the combined 
European and non-European trials, dronedarone was safe 
in maintaining sinus rhythm without major prolongation of 
either the QT or the QTc interval (lengthening by 23 and 
9 msec, respectively, without significant effects on the QRS Vascular Health and Risk Management 2009:5 639
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duration) with no reports of torsades. When analyzed sepa-
rately or in combination, dronedarone proved to be superior 
in maintaining sinus rhythm with an excellent safety and 
tolerability profile.
eRATO trial
The Efficacy and safety of dRonedArone for The cOntrol 
of ventricular rate during atrial fibrillation (ERATO) trial 
assessed the efficacy of dronedarone in the control of ven-
tricular rate in patients with permanent AF, when added 
to standard rate-control therapy.17 In this prospective, 
multinational, double-blind, randomized study, 174 elderly 
patients with permanent AF were randomized to 6 months’ 
treatment with dronedarone, 400 mg twice a day (n = 85) or 
matching placebo (n = 89). All patients were receiving stan-
dard rate-control therapy beta-blockers, calcium antagonists, 
and digoxin. In this study, 38.9% had structural heart dis-
ease and 39.7% had NYHA class I or II heart failure. The 
primary endpoint was the change in mean ventricular rate 
between baseline and day 14, as assessed by 24-hour Holter. 
Ventricular rate was also assessed during submaximal and 
maximal exercise.
At day 14, mean reduction in mean 24-hour ventricular 
rate in the dronedarone group was 11.0 bpm as opposed to 
an increase of 0.7 bpm in the placebo group, a treatment 
effect of –11.7 bpm (P  0.0001). Comparable reductions 
were sustained throughout the 6-month trial. During maxi-
mal exercise and compared to placebo, there was a mean 
reduction of 24.5 bpm (P  0.0001), without any reduction 
in exercise tolerance as measured by maximal exercise 
duration. The effects of dronedarone were additive to those 
of other rate-control agents, including beta-blockers, calcium 
antagonists, and digoxin. Thus, dronedarone appears to 
improve ventricular rate control in patients with permanent 
AF without any organ toxicity or proarrhythmia.
In the ERATO study, there was a mean 41.4% increase 
in digoxin levels in patients taking concomitant dronedarone, 
but without significant difference between the treatment 
groups in number of patients with an increase in digoxin 
outside the normal range (4.5% in the dronedarone group 
vs 2.8% in the placebo group). Also dronedarone had no 
effect on international normalized ratio in patients taking 
oral anticoagulants.
ANDROMeDA trial
In the EURIDIS and ADONIS trials, patients with NYHA 
class III and IV were excluded. The Antiarrhythmic Trial 
with Dronedarone in Moderate to Severe congestive heart 
failure Evaluating Morbidity Decrease (ANDROMEDA) 
study was double-blind, placebo-controlled, randomized 
in 1:1 ratio, parallel-group trial comparing treatment with 
400 mg of dronedarone twice daily with administration 
of matching placebo to assess the rate of hospitalization 
and mortality in patients with heart failure.18 Patients with 
symptomatic heart failure (NYHA class III or IV) requiring 
diuretic treatment, or paroxysmal nocturnal dyspnea within 
the month before admission with a left ventricular ejection 
fraction of 35% were enrolled. The study began in 
June 2002 and was originally scheduled to last for 2 years, 
and each patient was to be treated with dronedarone or 
matching placebo for a minimum of 12 months. However, 
in January 2003, the trial was terminated owing to an 
excess of deaths in the dronedarone group. Follow-up 
was continued until at least 6 months after withdrawal 
of the study drug. 627 patients had been enrolled (310 in 
dronedarone group and 317 in placebo group) and treated 
by the time the trial was stopped at a median follow-up 
of 2 months. During this period, 25 patients in the drone-
darone group (8.1%) and 12 patients in the placebo group 
(3.8%) died (hazard ratio in the dronedarone group, 2.13; 
95% CI 1.07 to 4.25; P = 0.03). The excess mortality was 
predominantly due to worsening of heart failure (10 deaths 
in the dronedarone group and 2 in the placebo group). After 
6 months of discontinuation of treatment, the mortality 
rates were comparable in both groups, 42 patients in the 
dronedarone group (13.5%) and 39 patients in the placebo 
group (12.3%) (hazard ratio, 1.13; 95% CI, 0.73 to 1.74; 
P = 0.60). The primary endpoint (death from any cause or 
hospitalization for worsening heart failure) did not differ 
significantly between the two groups; there were 53 events 
in the dronedarone group (17.1%) and 40 events in the 
placebo group (12.6%) (hazard ratio, 1.38; 95% CI, 0.92 
to 2.09; P = 0.12).
In the ANDROMEDA trial, the estimated glomerular 
filtration rate (EGFR) was decreased early after study treat-
ment was started in patients who received dronedarone. Mean 
EGFR was 7 mL per minute per 1.73 m2 of body-surface area 
lower in the dronedarone group than in the placebo group 
(P = 0.009). After treatment with the study drug was termi-
nated, EGFR returned to baseline values. However, the fall 
in EGFR may not reflect a deterioration of renal function. 
Dronedarone has been shown to reduce creatinine clearance 
by about 18%, with no evidence of an effect on the measured 
(as opposed to estimated) GFR, suggesting that dronedarone 
causes a specific partial inhibition of tubular organic cation 
transporters.19Vascular Health and Risk Management 2009:5 640
Patel et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
There was no evidence of proarrhythmia or an increased 
incidence of sudden death in the dronedarone group. 
Retrospective analysis of ANDROMEDA revealed an inap-
propriate discontinuation of angiotensin-converting enzyme 
inhibitor (ACEI)/angiotensin receptor blocker (ARB) in the 
dronedarone group after transient rise in serum creatinine 
levels early after the initiation of dronedarone. It is sus-
pected that inappropriate discontinuation of ACEI/ARB 
with subsequent pump failure may be a contributing factor 
for excess mortality. Other proposed explanations included 
negative ionotropic effect or the play of chance but the precise 
explanation is still not clear.
Of note, ANDROMEDA was not an AF study. A history 
or the presence of AF was not an inclusion criterion for this 
study. A history of AF (chronic, persistent, or paroxysmal) 
was reported in almost 40% of the patients, whereas AF at the 
time of randomization was present in 23.2% of the patients 
in the dronedarone group and 26.8% in the placebo group. 
Given the results of ANDROMEDA, dronedarone is not 
recommended for patients with NYHA class IV symptoms 
or cardiogenic shock.
ATHeNA trial
Post hoc analysis from the EURIDIS and ADONIS trial 
showed that dronedarone reduced the risk of all-cause 
hospitalization or death by 27% compared to placebo (95% 
CI 7% to 43%; P = 0.01).20 To elucidate this potential 
clinical benefit, the ATHENA (A Trial to Assess the Efficacy 
of Dronedarone for the Prevention of Cardiovascular 
Hospitalization or Death from any cause in Patients with Atrial 
Fibrillation/Atrial Flutter) was conducted recently.21 It was a 
prospective, randomized, placebo-controlled, double-blind, 
multi-national, multi-center, parallel-group trial evaluating the 
effects of dronedarone 400 mg bid versus placebo (ratio 1:1) 
in patients with paroxysmal or persistent AF/AFL who had 
additional risk factors for death. 4628 patients were enrolled, 
2301 received dronedarone and 2327 received placebo. The 
mean follow-up period was 21 months.
ATHENA was the landmark study that evaluated for 
the first time a treatment on the top of standard background 
therapy for the management of AF in reducing morbidity and 
mortality by preventing cardiovascular hospitalizations or 
death from any cause. It was the largest study ever conducted 
in a typical AF population (4628 patients were enrolled). 
The primary outcome was the first hospitalization due to 
cardiovascular events or death. This was the first large trial 
where a rhythm-control agent was studied with this primary 
endpoint in patients with AF/AFL. Secondary outcomes were 
death from any cause, death from cardiovascular causes, and 
hospitalization due to cardiovascular events. Patients enrolled 
in this study had one of the following risk factors: age overt 
70 years; arterial hypertension; diabetes mellitus; previous 
stroke or systemic embolism; left atrial enlargement; or left 
ventricular ejection fraction 40%. Therefore, the patients 
enrolled in ATHENA represent the largest group of individu-
als seeking medical attention for treatment of AF. Patients 
were ineligible for participation in ATHENA if they had 
one of the following cardiac conditions: permanent AF, 
unstable hemodynamic situation (ie, recently decompensated 
heart failure), or congestive heart failure NYHA class IV.
In the dronedarone group 734 (31.9%) had a primary 
outcome event and in the placebo group, 917 patients 
(39.4%) had a primary outcome event. The hazard ratio for 
the primary outcome in the dronedarone group was 0.76 
(95% CI, 0.69 to 0.84; P  0.001). There were 116 deaths 
(5.0%) in the dronedarone group and 139 (6.0%) in the 
placebo group (hazard ratio, 0.84; 95% CI, 0.66 to 1.08; 
P = 0.18). In the dronedarone group 63 patients died from 
cardiovascular causes (2.7%) while 90 (3.9%) patients died in 
the placebo group (hazard ratio, 0.71; 95% CI, 0.51 to 0.98; 
P = 0.03), largely due to a reduction in the rate of death from 
arrhythmia with dronedarone. There were 26 deaths from 
cardiac arrhythmia (in 1.1% of patients) in the dronedarone 
group and 48 (in 2.1%) in the placebo group (hazard ratio, 
0.55; 95% CI, 0.34 to 0.88; P = 0.01).
675 patients (29.3%) in the dronedarone group had a 
first hospitalization due to cardiovascular events compared 
with 859 patients (36.9%) in the placebo group (hazard 
ratio, 0.74; 95% CI, 0.67 to 0.82; P  0.001). This reduc-
tion in the rate of hospitalization due to cardiovascular 
events was mainly due to reduction in the number of 
hospitalizations for AF. Also hospitalization due to any 
cardiovascular event or death from any cause was less 
in the dronedarone group (1253 patients (54.5%)) vs 
1668 patients (71.7%) in the placebo group (hazard ratio, 
0.76; 95% CI, 0.68 to 0.84; P  0.001). Total hospital 
nights spent by the patients in the dronedarone group were 
significantly less than in the placebo group (9995 vs 13986; 
P 0.001). This reduction of almost 4000 hospital days 
translates to a decrease of 1.26 hospitalization days per 
patient per year. In patients with permanent AF there was 
26% drop in risk of cardiovascular hospitalization or death. 
They had a similar hazard ratio for the primary endpoint 
to the overall study population.22
The study drug was prematurely discontinued in 696 
(30.2%) of patients receiving dronedarone and in 716 (30.8%) Vascular Health and Risk Management 2009:5 641
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of those receiving placebo. The main reasons were adverse 
events. Bradycardia, QT-interval prolongation, diarrhea, 
nausea, rash, and an increase in the serum creatinine level 
were significantly more common in the dronedarone group 
than in the placebo group. No significant increase in the 
rates of thyroid or pulmonary disorders was seen with drone-
darone. The most frequently reported adverse events were 
gastrointestinal: 26% in dronedarone vs 22% in placebo.
The ATHENA trial concluded that treatment with drone-
darone significantly reduces the incidence of hospitaliza-
tion due to cardiovascular events or death in patients with 
paroxysmal or persistent AF/AFL. In a post-hoc analysis of 
the ATHENA trial, dronedarone was associated with a 34% 
decrease in adjusted risk of stroke compared with placebo 
over a follow-up averaging 21 months (1.19% per year in 
dronedarone group vs 1.79% per year in placebo group) 
(hazard ratio, 0.66; 95% CI, 0.46 to 0; P = 0.027).23
The ANDROMEDA study enrolled only patients with 
advanced heart failure and recent decompensation leading to 
hospitalization while patients with severe (NYHA class IV) 
heart failure were excluded in ATHENA. Given the results 
of both trials it is postulated that dronedarone increases 
cardiovascular mortality among patients with advanced and 
recently decompensated congestive heart failure but reduces 
cardiovascular mortality in patients with less severe heart 
failure.
On the basis of ANDROMEDA study, dronedarone 
failed in its first appearance before the US Food and Drug 
Administration (FDA) committee in August 2006. However, 
after the results of ATHENA study, dronedarone was resub-
mitted to the FDA and the European Medicines Agency for 
regulatory panel. On March 18, 2009 it was recommended by 
an Advisory Committee of the US FDA for approval in the 
management of AF. The FDA approved dronedarone 400 mg 
tablets on July 2, 2009 for AF/AFL (Multaq®; sanofi-aventis) 
with a boxed warning that the drug should not be used in 
severe heart failure patients.
DiONYSUS trial
In the Efficacy and Safety of Dronedarone vs Amiodarone 
for the maintenance of Sinus Rhythm in Patients with 
AF (DIONYSUS) trial, dronedarone was compared with 
amiodarone for the safety and efficacy in the maintenance 
of sinus rhythm in patients with AF (not AFL). 500 patients 
were involved in the study and had a follow-up of 6 months. 
Dronedarone was less effective for the maintenance of sinus 
rhythm. Rate of recurrent AF was 63% with dronedarone 
and 42% with amiodarone. But the use of dronedarone 
was associated with fewer side effects and less premature 
discontinuation of drug treatment.24
Conclusions
Dronedarone is a newer benzofuran derivative structurally 
similar to amiodarone except it lacks the iodine moiety 
and there is an addition of a methane sulfonyl group. 
It does not significantly prolong the QTc and no significant 
pulmonary, hepatic, ocular, or neurologic toxic effects have 
been observed in the studies done to date. Dronedarone, 
in addition to its benefits for rate and rhythm control, may 
reduce all-cause hospitalization or death in patients with AF. 
Dronedarone may be a viable, uniformly effective, and safer 
treatment option for patients with AF.
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